

CREUTZFELDT-JAKOB DISEASE POLICY

Committee Update

**Dorothy Scott, M.D., Senior Staff Fellow
Laboratory of Plasma Derivatives, Immunology Section
Division of Hematology, OBRR, CBER, FDA**

65th Meeting
March 16, 2000
Holiday Inn, Silver Spring
8777 Georgia Avenue
Silver Spring, MD

CJD Update

Blood Products Advisory Committee

March 17, 2000

- Revised Guidance published November 23, 1999 “Revised Precautionary Measures to Reduce the Possible Risk of Transmission of Creutzfeldt-Jakob Disease (CJD) and New Variant Creutzfeldt-Jakob Disease (nvCJD) by Blood and Blood Products”

Labeling Supplements

Implementation Queries

- Meeting of PHS Interagency Ad Hoc Working Group on nvCJD and Blood, November 17, 1999

Update on nvCJD epidemiology

Update on nvCJD laboratory experiments

- Current issues:

nvCJD cases in France

Degree of BSE exposure in European countries other than the United Kingdom

Plan: TSE Advisory Committee to address French nvCJD cases, and questions of BSE surveillance and exposure in Europe on June 1, 2000